GlassScriptPhysician profile
Ankit Madan
NPI 1063791119
$10,406.07
in general payments reported to CMS, 2019-2025
53 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,268 · 2020: $1,202 · 2021: $621 · 2022: $710 · 2023: $206 · 2024: $25.20 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $5,425.45 | 2019-2020 | |
| Pfizer INC. | $478.91 | 2019-2025 | |
| Astellas Pharma US INC | $460.22 | 2019-2025 | Padcev, Vyloy |
| Janssen Biotech, INC. | $442.94 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $327.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $285.25 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $268.36 | 2019-2021 | |
| Genzyme Corporation | $197.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $193.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $187.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $177.94 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.52 | 2019-2020 | |
| Lilly USA, LLC | $150.54 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Amgen INC. | $117.13 | 2019-2020 | |
| Incyte Corporation | $110.64 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Madan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.